 |
Open for inclusion |
A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab (anti-PD-1 Monoclonal Antibody) and in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant TumorsCancer type: Lung cancer, Melanoma Phase: I/II Principal Investigator: Hedman Mattias Country: SE Keywords: Sweden, Stockholm, BMS986205 Status: Open for inclusion Link to Clinicaltrials.gov: https://clinicaltrials.gov/ct2/show/NCT02658890 |